Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) — Meletios-Athanasios (Thanos) C Dimopoulos, MD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Robert Z Orlowski, MD, PhD

CME information and select publications

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49)
• PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24)
• Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38)

NCPD information and select publications

Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics:

Introduction (0:00)

• New Biology of Myelofibrosis (1:55)
• Novel Regulatory T-Cell Infusion Therapy (14:57)
• Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39)
• BET Inhibitors: Pelabresib (42:03)
• Navtemadlin (53:20)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 1: Current Management of Myelofibrosis (MF) — Professor Claire Harrison

CME information and select publications

Featuring perspectives from Dr Sunnie Kim, Ms Brooke Parker, Ms Michal Segal and Dr Manish Shah, including the following topics:

• Introduction: Clinical Presentation of Gastroesophageal Cancer (0:00)
• Management of Localized or Locally Advanced Gastroesophageal Cancers; Current and Future Role of Immune Checkpoint Inhibitors (21:44)
• Incorporation of Immunotherapeutic Strategies for HER2-Negative Metastatic Gastroesophageal Tumors (39:32)
• Role of Therapy Targeting CLDN18.2 in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (1:00:50)
• Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers (1:22:41)

NCPD information and select publications

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics:

• Introduction: Actionable Genomic Alterations (0:00)
• ALK (9:49)
• ROS1 (22:22)
• HER2 (31:00)
• RET (38:52)
• NTRK (45:30)
• MET (46:31)
• Novel Targeted Strategies (49:09)
• BRAF (54:19)
• KRAS G12C (55:38)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting HER2, MET, BRAF and KRAS G12C — Joel W Neal, MD, PhD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting ALK, ROS1, RET, TRK and NRG1 — Jessica J Lin, MD

CME information and select publications